Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support–free days within 21 days.

The aspirin and P2Y12 inhibitor groups met the predefined criteria for equivalence at an adaptive analysis and were statistically pooled for further analysis.

Enrollment was discontinued after the prespecified criterion for futility was met for the pooled antiplatelet group compared with control.

Among the 1,557 critically ill patients randomized, 8 patients withdrew consent and 1,549 completed the trial.

The median for organ support–free days was 7 (IQR, −1 to 16) in both the antiplatelet and control groups.

Read More